Literature DB >> 25301048

Metastasis-associated protein 1 expression in oral squamous cell carcinomas: correlation with metastasis and angiogenesis.

Azadeh Andishehtadbir, Ali Dehghani Najvani, Soheil Pardis, Zohreh Jafari Ashkavandi, Mohammad Javad Ashraf, Bijan Khademi, Fereshteh Kamali.   

Abstract

OBJECTIVE: Metastasis-associated protein 1 (MTA1) has been associated with poor prognosis in several carcinomas. Recent investigation has found that in different tumors, MTA1 protein significantly correlates with tumor angiogenesis, suggesting that MTA1 may be a possible angiogenesis-promoting molecule in malignant tumors. Thus, the current study was performed to determine the role of MTA1 protein in the biological behavior of oral squamous cell carcinoma and its relation with tumor angiogenesis. MATERIAL AND
METHOD: In this study, 44 oral squamous cell carcinomas and 15 normal epitheliums were reviewed by IHC staining for MTA1 and CD105.
RESULTS: Frequency of MTA1 expression in SCCs was recorded as 97.7%, which was significantly higher than that of the control group (33.3%). Mean percentage of MTA1 expression in oral squamous cell carcinomas was 76.88 ± 25.33% which was significantly higher than that of the control group (22.81 ± 10.83). Our data showed a correlation between MTA1 expression with lymph node metastasis, tumor size and, stage. Evaluation of the correlation between MTA1 protein expression and micro vessel density showed that high micro vessel density was detected more frequently in tumors with MTA1 protein overexpression than in those without overexpression.
CONCLUSION: In the present study, high expression of the MTA1 protein was seen in oral squamous cell carcinoma, and was closely associated with tumor progression and increased tumor angiogenesis. The findings may indicate that MTA1 protein has clinical potentials as a useful indicator of progressive phenotype, a promising prognostic predictor to identify patients with poor prognosis and may be a potential novel therapeutic target of anti-angiogenesis for patients with oral squamous cell carcinoma.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25301048     DOI: 10.5146/tjpath.2014.01277

Source DB:  PubMed          Journal:  Turk Patoloji Derg        ISSN: 1018-5615


  7 in total

1.  MTA1 regulation of ERβ pathway in salivary gland carcinoma cells.

Authors:  Kazufumi Ohshiro; Rakesh Kumar
Journal:  Biochem Biophys Res Commun       Date:  2015-07-11       Impact factor: 3.575

2.  Increased expression of high-mobility group nucleosomal-binding domain 2 protein in various tumor cell lines.

Authors:  Qian Li; Jiao Chen; Xiaoying Li; Bomiao Cui; Yaping Fan; Ning Geng; Qianming Chen; Ping Zhang; Yun Feng
Journal:  Oncol Lett       Date:  2018-01-29       Impact factor: 2.967

3.  MTA1 Expression in Benign and Malignant Salivary gland Tumors.

Authors:  Azadeh Andisheh-Tadbir; Ali Dehghani-Nazhvani; Mohammad Javad Ashraf; Bijan Khademi; Hosein Mirhadi; Shima Torabi-Ardekani
Journal:  Iran J Otorhinolaryngol       Date:  2016-01

4.  Clinicopathological Significance of MTA 1 Expression in Patients with Non-Small Cell Lung Cancer: A Meta-Analysis

Authors:  Wei Zhu; Guixian Li; Haina Guo; Honglang Chen; Xiujuan Xu; Jiali Long; Chao Zeng; Xiaojun Wang
Journal:  Asian Pac J Cancer Prev       Date:  2017-11-26

5.  Prognostic and clinical significance of metastasis-associated gene 1 overexpression in solid cancers: A meta-analysis.

Authors:  Ke Ma; Yangwei Fan; Yuan Hu
Journal:  Medicine (Baltimore)       Date:  2018-10       Impact factor: 1.817

6.  High Expression of MTA1 Predicts Unfavorable Survival in Patients With Oral Squamous Cell Carcinoma.

Authors:  Kuan-Yu Lin; Tzu-Cheng Su; Chung-Min Yeh; Wan-Ru Chao; Wen-Wei Sung
Journal:  In Vivo       Date:  2021 Jul-Aug       Impact factor: 2.155

7.  MiR-543 promotes tumorigenesis and angiogenesis in non-small cell lung cancer via modulating metastasis associated protein 1.

Authors:  Dawei Wang; Li Cai; Xudong Tian; Wenjun Li
Journal:  Mol Med       Date:  2020-05-14       Impact factor: 6.376

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.